美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Range Cancer Therapeutics ETF

9.02

0.0000

成交量：- -

成交額：- -

市值：704.29萬

市盈率：23.74

高：9.02

開：9.02

低：9.02

收：9.02

52周最高：9.02

52周最低：9.02

股本：78.08萬

流通股本：78.08萬

量比：- -

換手率：- -

股息：0.00

股息率：0.01%

每股收益(TTM):0.3800

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

FDA授予Xellsmart帕金森病現貨型細胞療法快速通道資格

环球市场播报

中信建投：解鎖不可成藥靶點，RAS藥物打開腫瘤治療新格局

【券商聚焦】中信建投：解鎖不可成藥靶點，RAS藥物打開腫瘤治療新格局

中信建投：解鎖不可成藥靶點 RAS藥物打開腫瘤治療新格局

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/CNCR"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CNCR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CNCR\",,,,,undefined,":{"symbol":"CNCR","market":"US","secType":"STK","nameCN":"Range Cancer Therapeutics ETF","latestPrice":9.02,"timestamp":1787342400000,"preClose":9.02,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":780814,"shares":780814,"eps":0.38,"marketStatus":"休市中","change":0,"latestTime":"08-21 16:00:00 EDT","open":9.02,"high":9.02,"low":9.02,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0.38,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":9.02,"sharesOutstanding":780814,"nav":8.9,"aum":6949244.6,"dividendRate":0.000111,"bidAskSpread":0,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CNCR\",,,,,undefined,":{"symbol":"CNCR","floatShares":780814,"roa":"--","roe":"--","lyrEps":0,"shares":780814,"dividePrice":0.001,"high":9.02,"amplitude":0,"preClose":9.02,"low":9.02,"week52Low":9.02,"pbRate":"--","week52High":9.02,"institutionHeld":0,"latestPrice":9.02,"eps":0.38,"divideRate":0.000111,"volume":0,"delay":0,"ttmEps":0.38,"open":9.02,"prevYearClose":9.02,"prevWeekClose":9.02,"prevMonthClose":9.02,"prevQuarterClose":9.02,"fiveDayClose":9.02,"twentyDayClose":9.02,"sixtyDayClose":9.02},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CNCR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-28","symbol":"CNCR","reason":null,"defaultRemindTime":1748439000000,"announcedDate":"2025-05-27","type":"delisting","dateTimestamp":1748404800000},{"market":"US","date":"2021-12-29","symbol":"CNCR","amount":1.8533352,"defaultRemindTime":1640788200000,"name":"Loncar Cancer Immunotherapy ETF","recordDate":"2021-12-31","payableDate":"2021-12-30","currency":"USD","type":"dividend","dateTimestamp":1640754000000},{"market":"US","date":"2020-12-30","symbol":"CNCR","amount":0.2881193,"name":"Loncar Cancer Immunotherapy ETF","recordDate":"2021-01-04","payableDate":"2020-12-31","currency":"USD","type":"dividend","dateTimestamp":1609304400000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CNCR\",market:\"US\",,,undefined,":[{"executeDate":"2020-12-30","recordDate":"2020-12-31","paymentDate":"2021-01-04","value":0.2881193,"currency":"USD"},{"executeDate":"2021-12-29","recordDate":"2021-12-30","paymentDate":"2021-12-31","value":1.8533352,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CNCR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CNCR\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2656875551","title":"FDA授予Xellsmart帕金森病現貨型細胞療法快速通道資格","url":"https://stock-news.laohu8.com/highlight/detail?id=2656875551","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656875551?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 21:07","pubTimestamp":1785848846,"startTime":"0","endTime":"0","summary":"XellSmart专有的现货型iPSC衍生细胞疗法XS411获得美国FDA快速通道资格，标志着其全球临床开发的重要里程碑。　　2026年7月28日，XellSmart宣布，其自主研发的针对帕金森病的同种异体、现货型、可注射iPSC衍生细胞疗法候选产品XS411，已正式获得美国食品药品监督管理局授予的快速通道资格。这一监管认定彰显了美国卫生监管机构对XS411临床价值及其解决帕金森病治疗中重大未满足临床需求潜力的认可，是其全球临床开发和未来市场准入的关键里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-08-04/doc-inimeknz5555117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["SYNB","BK4585","BK4588","LABU","CNCR","WDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656346962","title":"中信建投：解鎖不可成藥靶點，RAS藥物打開腫瘤治療新格局","url":"https://stock-news.laohu8.com/highlight/detail?id=2656346962","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656346962?lang=zh_tw&edition=fundamental","pubTime":"2026-08-03 07:56","pubTimestamp":1785715006,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CNCR","CANC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652473201","title":"【券商聚焦】中信建投：解鎖不可成藥靶點，RAS藥物打開腫瘤治療新格局","url":"https://stock-news.laohu8.com/highlight/detail?id=2652473201","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652473201?lang=zh_tw&edition=fundamental","pubTime":"2026-07-17 08:56","pubTimestamp":1784249779,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指，RAS是人类肿瘤中最重要的致癌驱动基因家族之一，主要包括KRAS、NRAS和HRAS，其中KRAS占据核心地位。 RAS靶向治疗已从G12C单点突破，进入G12D、Pan-KRAS和Pan-RAS(ON)多路线推进阶段，管线布局和临床验证正在逐步丰富。2026年ASCO大会上，RMC-6236在2L转移性胰腺癌III期研究中取得积极结果，中位OS较化疗接近翻倍，进一步强化了市场对RAS靶向治疗临床价值的期待。国内企业也在G12D、Pan-RAS、Pan-KRAS等多方向积极跟进。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/NWI3NDNkNGUxZmM1MTMzOTE0MzEwMTk=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NWI3NDNkNGUxZmM1MTMzOTE0MzEwMTk=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986095","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0737861772.HKD","LU2488822045.USD","BK1583","BK1209","KCE","LU0329678337.USD","06078","CANC","BK0276","LU0329678170.USD","601066","CNCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652781264","title":"中信建投：解鎖不可成藥靶點 RAS藥物打開腫瘤治療新格局","url":"https://stock-news.laohu8.com/highlight/detail?id=2652781264","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652781264?lang=zh_tw&edition=fundamental","pubTime":"2026-07-17 08:00","pubTimestamp":1784246446,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CNCR","CANC"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/CNCR\",params:#limit:6,delay:false,,,undefined,":[]}}